Alpha Teknova

Biopharma R&D And Cell Therapy Will Drive Custom Manufacturing

AnalystHighTarget

Not Invested

Consensus Narrative from 3 Analysts

Published

08 Aug 25

Updated

21 Aug 25

AnalystHighTarget's Fair Value

US$12.00

61.9% undervalued

21 Aug

US$4.57

-0.7%

3.6%

-0.7%

3.6%

Author's Valuation

US$12.0

61.9% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$12.0

61.9% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

14.00%

Life Sciences revenue growth rate

0.32%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.38%

Calculation

US$7.43m

Earnings '28

107.90x

PE Ratio '28

US$802.21m

Market Cap '28

US$802.21m

Market Cap '28

54.14m

No. shares '28

US$14.82

Share Price '28

US$14.82 Share Price '28

Discounted to 2025 @ 7.38% p.a.

US$11.97

Fair Value '25